Orientadores: Maricilda Palandi de Mello, Fernanda Caroline Soardi / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-25T03:55:23Z (GMT). No. of bitstreams: 1 Petroli_ReginaldoJose_D.pdf: 6228632 bytes, checksum: e6e99d402e3d99ccab57c84290065e84 (MD5) Previous issue date: 2014 / Resumo: O receptor de andrógenos (AR) é um fator de transcrição pertencente à superfamília de receptores nucleares e é ativado por fosforilação e dimerização sob a ligação ao hormônio. Várias funções são atribuídas a este receptor, sendo a principal delas o desenvolvimento e manutenção das características sexuais masculinas, atua na regulação da expressão gênica e diferenciação celular em tecidos alvos. O presente trabalho teve por objetivo principal a análise do efeito das mutações p.Pro695Ser, p.Ser759Tre, p.Leu768Val., p.Cis806Fen+p.Gln798Glu, p.Leu830Fen, p.Ile898Fen e p.Pro904Arg sobre a função do AR. As mutações acima citadas, localizadas no domínio de ligação ao hormônio, foram identificadas por sequenciamento direto do gene do AR de pacientes 46,XY com diferentes graus da Síndrome da Insensibilidade Androgênica (AIS). Mutações nesse domínio geralmente rompem a ligação aos andrógenos naturais, porém há algumas que não afetam essa ligação, mas interferem na interação entre os domínios amino e carboxi-terminal (N/C terminal), importante para a estabilização receptor-ligante. Assim, ambas funções foram investigadas. Para se avaliar a capacidade de transativação das proteínas AR mutantes, foi realizada a técnica de mutagênese sítio dirigida no cDNA completo, seguida de transfecção e expressão em células e mamíferos e, análise de transativação induzida por concentrações crescentes de 5?-diidrotestosterona (DHT) utilizando-se um gene repórter. A análise das interações N/C-terminal para cada AR mutante foi realizada pela técnica de duplo-híbrido em células de mamíferos. A mutação p.Pro695Ser apresentou atividades de transativação de 85% e 82% nos ensaios transativação com o cDNA completo e no duplo-híbrido, respectivamente, em valores de DHT fisiológicos (cerca de 1 nM). As atividades atingiram valores normais em concentrações elevadas de DHT indicando um baixo efeito sobre a atividade gonadal. No entanto, em concentrações de DHT inferiores a atividade de transativação decai para menos de 50% nos dois experimentos, podendo afetar as funções do AR em tecidos não gonadais. Esta mutação foi considerada "branda" e corresponde perfeitamente ao fenótipo masculino do paciente que se apresentava com ginecomastia, mas com fertilidade preservada. Com 1 nM de hormônio, as mutações p.Ser759Tre, p.Leu830Fen, p.Ile898Fen apresentaram atividade de transativação superior a 20%, havendo um aumento de resposta com concentrações crescentes. No entanto, o comportamento de cada uma no experimento de interação N/C diferiu sendo que a p.Ile898Fen não apresentou atividade em nenhuma concentração de ligante; as p.Ser759Tre e p.Leu830Fen responderam positivamente ao aumento da concentração de DHT atingindo 50% e 250% da atividade trancricional do receptor selvagem, respectivamente. Esses resultados indicam um fenótipo parcial de AIS (PAIS) para os portadores das mutações p.Ser759Tre e p.Leu830Fen. Nesses casos verificou-se uma boa correlação dos achados funcionais com os fenótipos dos pacientes que apresentavam graus variados de PAIS. Já para a mutação p.Ile898Fen o fenótipo esperado baseando-se nos resultados funcionais seria o de AIS na forma completa (CAIS), porém os pacientes portadores desta mutação apresentavam graus variados de ambiguidade genital compatíveis com o fenótipo PAIS. Isto indica que outros fatores devem estar influenciando a manifestação fenotípica nesse caso. A mutação p.Leu768Val apresentou atividade transcricional nula em 1 nM de DHT nos dois experimentos, um perfil típico do fenótipo CAIS apresentado pelo portador desta mutação. As mutações p.Gln798Glu e p.Cis806Fen estudadas separadamente apresentaram respostas à indução de DHT semelhantes às de mutações "brandas" e PAIS, respectivamente. No entanto, quando estudadas em conjunto, a atividade de transativação com 1 nM foi inferior a 10%, aumentando com o aumento da concentração de ligante, comportamento compatível com mutações mais graves resultando no fenótipo CAIS observado nesse caso. Por último, a mutação p.Pro904Arg, embora tenha reduzido a atividade trancricional para cerca de 20% da selvagem no experimento com o cDNA completo, no experimento com duplo híbrido a atividade foi nula indicando uma ação mais grave compatível com a forma CAIS observada. A análise funcional do AR aqui realizada pode elucidar alguns mecanismos moleculares associados a cada mutação, bem como pode fornecer subsídios para a resposta ao tratamento com DHT em cada caso em particular / Abstract: The androgen receptor (AR) is a transcription factor that belongs to the superfamily of nuclear receptors activated by phosphorylation and dimerization by hormone binding. Several functions are attributed for AR, like male sex development, regulation of gene expression and cell differentiation in target tissues. The aim of this study was to analyze the effect of mutations p.Pro695Ser, p.Ser759Tre, p.Leu768Val, p.Cys806Phe+ p.Gln798Glu, p.Leu830Phe, p.Ile898Phe and p.Pro904Arg upon AR transactivation activity. All mutations studied here are located in the hormone-binding domain and were identified in patients with different degrees of androgen insensitivity syndrome (AIS) by AR gene sequencing. Mutations in this domain can result in the impairment of androgen ligation, but there are cases that it does not affect the binding but interfere with the interaction between the amino and carboxi-terminal domains (N/C terminal), important step for receptor-binding stabilization. Thus, both functions have been studied in this work. To evaluate the ability of AR transactivation of mutant proteins, the site-directed mutagenesis assay was performed on full-length cDNA, followed by transfection and expression in mammalian cells. The analysis of transactivation of a reporter gene with different dihydrotestosterone (DHT) concentrations was performed. The analysis of N/C-terminal interactions for each mutant AR was performed by two- hybrid mammalian assay. The mutation p.Pro695Ser reveled transactivation activities of 85% and 82% in transactivation assays with the full-length cDNA and two hybrid assay, respectively, at DHT physiological values (approximately 1 nM). The activities reached normal values at high DHT concentrations, indicating a low effect on gonadal activity. However, in low DHT concentrations, the transactivation activity decays to less than 50% in both experiments, which may affect AR functions in non-gonadal tissues. This mutation was considered "mild" and corresponds perfectly to the male phenotype of the patient who presented with gynecomastia, but with preserved fertility. With 1 nM hormone, the p.Ser759Tre, p.Leu830Phe, p.Ile898Phe mutations showed transactivation activity higher than 20%, the response increased with higher DHT concentrations. However, in N/C interaction assays, those mutations showed different results. The p.Ile898Phe revealed a complete disruption in N/C interaction at all hormone concentrations; the p.Ser759Tre and p.Leu830Phe showed positive response with the increasing in DHT concentrations and reached 50% and 250% of the transcriptional activity of wild type, respectively. Such results indicate a partial AIS phenotype (PAIS) as functional effect for p.Ser759Tre and p.Leu830Phe. In these cases there was a positive correlation with the phenotypes of patients that presented different degrees of PAIS. For the p.Ile898Phe, the expected phenotype based on functional analysis would be the complete form of AIS (CAIS), but the patients with this mutation had variable degrees of genital ambiguity consistent to PAIS. This indicates that other factors must influence the phenotypic manifestation. The p.Leu768Val revealed a complete disruption at 1 nM DHT in both experiments, typical of CAIS. The p.Gln798Glu and p.Cys806Phe mutations studied separately revealed responses to the induction of DHT similar to Mild and Partial phenotypes, respectively. However, when analyzed together, the transactivation activity of 1 nM was lower than 10%, increasing in high ligand concentration, which is consistent to CAIS phenotype. Finally, p.Pro904Arg, although showed residual transcriptional activity around 20% of the wild type in the experiment with the full-length cDNA, it abolished the transcriptional activity when N/C terminal interaction was tested indicating a CAIS phenotype, as observed in the patient. Functional analysis of the AR performed here could elucidate some molecular mechanisms associated with each mutation, and may provide a basis for response to treatment with DHT in each particular case / Doutorado / Genetica Animal e Evolução / Doutor em Genetica e Biologia Molecular

Aberrant androgen receptor (AR) activity plays a critical role in the development and progression of both early-staged organ-confined and late-staged metastatic human prostate cancer. Recent large-scale genomic sequencing studies showed that ~50% of organ-confined prostate cancer patients have genetic rearrangements that placed the ETS transcription factors (e.g. ERG, ETV1) under the control of androgen-regulated gene promoters such as TMPRSS2. This results in the upregulation of the ETS transcription factors’ expressions in the presence of androgens. The aberrant overexpression of the ETS transcription factors are shown to induce the expression of genes that promote the cellular motility and invasive potential of prostate-tumor cells. Moreover, the improved therapeutic outcome of the second-generation anti-androgen therapies (e.g. abiraterone and enzalutamide) are encouraging, and prove that aberrant AR activity still drives the progression of metastatic prostate cancer. Although these treatments are initially effective, these cancer cells eventually develop resistance to these AR-targeted therapies termed castration-resistant prostate cancer (CRPC). Since the molecular steps involved in AR activation is still not clearly defined, it is critical to define the interactions required for AR activation prostate cancer cells, which will provide a framework for establishing more effective treatments to inhibit aberrant AR activity in human prostate cancer cells. Here, I developed a cellular system to isolate ligand-dependent interactions of AR in prostate-tumor cells. A siRNA luciferase screen was also developed and identified novel modulators of AR-mediated transcription selected from the proteomic dataset. Further biochemical studies showed that AR is associated with the Golgi membrane in a ligand-sensitive manner. And that the nuclear localization of ARA160, an AR coactivator, is regulated by the COPI retrograde trafficking machinery. Collectively, these results support the use of this cellular system to decipher the known AR-interacting proteins and novel components involved in AR signaling in prostate-tumor cells. I next investigated the androgen-sensitive AR transcriptional complexes and androgen-sensitive microsomes isolated from LNCaP prostate-tumor cells. Both studies yielded results that would further strengthen the diverse AR actions mediated within the cell. These results further support the notion that there is significant crosstalk amongst different cell surface receptor signaling pathways with AR. An extension of the androgen-sensitive microsome findings also led us to study the androgen-sensitive G-protein coupled receptor, CXCR7. I showed that androgens regulate the expressions of CXCR7 and CXCR4 and in turn modulated CXCL12-mediated motility in prostate tumor cells. Lastly, biochemical strategies were developed to detect differences in glycoprotein expression of frozen prostate cancer tissues isolated from human patients. I showed that the workflow successfully solubilized and isolated N- and O-linked glycoproteins from the frozen tissue samples and can be analyzed by quantitative mass spectrometry. This workflow would thus facilitate future biomarker studies. In summary, these data demonstrate the utility of developing methods for the comprehensive mapping of AR-mediated signaling in prostate cancer cells, and thus provide novel target candidates for the therapeutic treatment of metastatic or CRPC.

No description available.

No description available.

BACKGROUND:Retrotransposons have been suggested to provide a substrate for non-allelic homologous recombination (NAHR) and thereby promote gene family expansion. Their precise role, however, is controversial. Here we ask whether retrotransposons contributed to the recent expansions of the Androgen-binding protein (Abp) gene families that occurred independently in the mouse and rat genomes.RESULTS:Using dot plot analysis, we found that the most recent duplication in the Abp region of the mouse genome is flanked by L1Md_T elements. Analysis of the sequence of these elements revealed breakpoints that are the relicts of the recombination that caused the duplication, confirming that the duplication arose as a result of NAHR using L1 elements as substrates. L1 and ERVII retrotransposons are considerably denser in the Abp regions than in one Mb flanking regions, while other repeat types are depleted in the Abp regions compared to flanking regions. L1 retrotransposons preferentially accumulated in the Abp gene regions after lineage separation and roughly followed the pattern of Abp gene expansion. By contrast, the proportion of shared vs. lineage-specific ERVII repeats in the Abp region resembles the rest of the genome.CONCLUSIONS:We confirmed the role of L1 repeats in Abp gene duplication with the identification of recombinant L1Md_T elements at the edges of the most recent mouse Abp gene duplication. High densities of L1 and ERVII repeats were found in the Abp gene region with abrupt transitions at the region boundaries, suggesting that their higher densities are tightly associated with Abp gene duplication. We observed that the major accumulation of L1 elements occurred after the split of the mouse and rat lineages and that there is a striking overlap between the timing of L1 accumulation and expansion of the Abp gene family in the mouse genome. Establishing a link between the accumulation of L1 elements and the expansion of the Abp gene family and identification of an NAHR-related breakpoint in the most recent duplication are the main contributions of our study.

CTCs have emerged as a potential source of clinical significance. But with numerous isolating systems currently available, the numbers of captured CTCs vary widely. At this point, CellSearch remains the only FDA-approved system with clinical significance whereby the results could be used to monitor patients with metastatic colon, breast, or prostate cancer. However, its inability to isolate CTCs from non-high risk prostate cancer patients or CTCs that are EpCAM-negative has led to criticism. In this study, we have shown that size-based filtration successfully isolates CTCs from patients with localized and metastatic prostate cancer. We have also shown that CTCs can be successfully isolated from low and intermediate risk groups. Additionally, clusters of CTCs were preserved and isolated in all localized risk groups and metastatic patients. Furthermore, we enumerated the isolated CTCs using automated and manual methods in low risk, intermediate risk, high risk, and metastatic prostate cancer. The automated and manual counts were comparable. Moreover, the amounts of clusters and the size of clusters correlated with the status and stage of prostate cancer. / October 2016

<p>The androgen receptor (AR) signaling axis is a well-established therapeutic target in prostate cancer, due to its central role in tumor maintenance and progression. Although patients respond initially to androgen deprivation therapies and AR antagonists, they invariably progress to a castration-resistant state. Consequently, there is an unmet need for agents that target the AR signaling axis in a unique manner. </p><p>Histone deacetylase (HDAC) inhibitors repress AR signaling and prostate cancer growth in cellular and xenograft models. However, HDAC inhibitors also induce epithelial to mesenchymal (EMT) and neuroendocrine differentiation, both of which are associated with prostate cancer progression and aggressiveness. Given that 18 different HDAC isoforms have been identified in humans, and non-selective or Class I (HDAC1, 2, 3, and 8) HDAC inhibitors have been used in most of these studies, the relative contribution of individual HDAC isoforms to AR transcriptional activity and prostate cancer pathophysiology remains to be elucidated. The overarching goals of this study were to (1) determine the role of individual Class I HDACs in AR transcriptional activity and prostate cancer growth, (2) identify selective HDAC inhibitors that have reduced adverse profiles to the treatment of prostate cancer, and (3) identify potential HDAC-interacting proteins that regulate AR target gene transcription and prostate cancer growth. </p><p>Using genetic knockdown studies and pharmacological inhibitors with isoform selectivity, we identified that HDAC3 was required for AR transcriptional activity and proliferation in cellular models of androgen-sensitive and castration-resistant prostate cancer (CRPC). Additionally, we found that RGFP966, an HDAC3-selective inhibitor, attenuated the growth of a xenograft model of CRPC. Furthermore, non-selective HDAC inhibitors induced EMT and neuroendocrine markers in prostate cancer cells, but RGFP966 treatment did not. These studies provide rationale for selective inhibition of HDAC3 for the treatment of CRPC, and could provide an explanation for the lack of success using non-selective HDAC inhibitors in clinical trials for prostate cancer.</p><p>We also assessed the role of REV-ERB alpha, an HDAC3-interacting protein, in the regulation of AR transcriptional activity and prostate cancer growth. Using siRNA knockdown studies, REV-ERB inhibitors, and overexpression studies, we concluded that REV-ERB alpha; was required for AR target gene induction and prostate cancer growth, including models of CRPC. These studies also provide rational for targeting REV-ERB alpha; for the treatment of CRPC.</p><p>Taken together, these studies identify two novel targets in the HDAC signaling axis for the treatment of prostate cancer: HDAC3 and REV-ERB alpha. Our studies provide greater insight into AR transcriptional regulation and prostate cancer pathophysiology.</p> / Dissertation

Two distinct nonapeptide systems, consisting of the vasotocin- and oxytocin-related peptides have evolved in vertebrates, and their role in male reproduction is well-described in mammals. In contrast, their comparative role in reproduction in basal vertebrate species, and teleost fishes in particular, has not been investigated in great detail. Using two cyprinid species, the zebrafish (D. rerio) and the goldfish (C. auratus), I address the hypothesis that the teleost nonapeptides vasotocin and isotocin stimulate male cyprinid reproductive physiology by affecting central neuronal and/or peripheral endocrine pathways. To test this hypothesis in zebrafish, an indeterminate breeder, I conducted pharmacological inhibition experiments employing vasotocin and isotocin-specific antagonists in males, a treatment predicted to inhibit reproductive success in mating trials. Because nonapeptides can act both as central peptide neuromodulators and as secreted hormone, I further quantified indices of male courtship behavior (nudging, circling and chasing) and major androgens (testosterone and 11-keto-testosterone) as key endocrine indices of the male reproductive axis. Together, these experiments revealed a dose-dependent, differential inhibition of spawning success, with significant reductions (-65%) in egg fertilization rate observed in pairs in which males had been i.p. injected with 5 ng/g vasotocin and significant reductions (-79%) observed at 500 ng/g i.p injected isotocin. In either case, these partial inhibitions of reproductive success were correlated with significant decreases in specific indices of male courtship behavior, but not endocrine indices, suggesting that individual nonapeptides mediate their effects via central modulation of behavioural neurocircuits. Interestingly, a co-administration of vasotocin and isotocin antagonists completely abolished reproductive success, however this effect was neither correlated with decreases in male courtship behavior, nor endocrine indices, suggesting a separate mode of action, possibly at the level of male pheromone release. To further probe the role of nonapeptides in male zebrafish reproduction, I subsequently tested the hypothesis that nonapeptide systems are acutely activated by key reproductive cues, specifically the releaser pheromone PGF2α, which serves as a chemoattractant and acutely stimulates male reproductive behavior in male cyprinids. Using a chemoattractant choice assay in conjunction with immunohistochemistry and gene expression approaches, I determined whether male zebrafish are attracted to pheromonal cues and acutely activate isotocinergic neurons in the short term and/or regulate nonapeptide gene expression in the longer term. My results show that individual male zebrafish are attracted to PGF2α in an acute choice test. Furthermore, an increase in p-ERK immunoreactivity, a marker of neuronal activation, was observed in the olfactory bulb 10 min following exposure, suggesting a specific response to the pheromone compared to EtOH vehicle. However, no co-localization of p-ERK and IT-positive perikarya was observed in the preoptic area (POA), refuting the hypothesis that PGF2α exposure acutely activates isotocinergic neurons in zebrafish. Analysis of whole brain relative mRNA transcript abundance revealed that PGF2α exposure time-dependently regulates whole brain isotocin, but not vasotocin transcript abundance, suggesting secondary longer-term effects of PGF2α exposure on the isotocinergic system. Using an analogous experimental approach, I further tested the hypothesis that nonapeptides stimulate male reproductive physiology in goldfish, a determinate breeder. Sexually mature male goldfish pretreated with saline or vasotocin or isotocin antagonists were exposed to saline or PGF2α-injected stimulus females and male courtship behavior (chasing, circling), endocrine indices (circulating testosterone) and milt release were quantified. Both nonapeptide antagonists reduced strippable male milt quantity in response to PGF2α-injected females, suggesting a neuronal or hormonal action of both nonapeptides on goldfish milt release. Together, I show that nonapeptides contribute to male reproductive physiology in two species of cyprinids with different reproductive tactics. However, the mode of action may differ from one species to another, with evidence suggesting that nonapeptides play a role in the regulation of reproductive behavior and, possibly, male pheromone, release in zebrafish, while effects on male goldfish seem to be exclusively related to the release of milt. Future studies should compare other teleost species with specific reproductive biology and focus on the gonadal roles of nonapeptides in sperm maturation and/or release.

Androgens are essential for the maintenance of male health and wellbeing. A disturbance in androgen signalling has been associated with a number of clinically relevant disorders such as cardiovascular disease, diabetes and metabolic disorders as well as infertility. Primarily produced in the testis in males, the actions of androgens are mediated through binding to androgen receptor (AR), a member of the nuclear receptor superfamily of ligand-activated transcription factors. The somatic cells of the testis are known to have a number of key roles in both testis function and development and the Sertoli, Leydig and Peritubular Myoid cells are known to express AR in adulthood. It is through AR that some testicular functions are mediated; for example, the Sertoli cells support of complete spermatogenesis with Sertoli cell androgen receptor knockout (SCARKO) testis demonstrating a halt of spermatogenesis before meiosis. However, how androgen signalling is impacting testicular function through each of the somatic cell types is not yet fully understood. Currently, treatments for male reproductive disorders such as hypogonadism (low androgens) and infertility are limited to treatment of the symptoms; using androgen replacement therapy and in vitro fertilisation techniques. This has been, up until recently, a result of a lack of understanding of the causes of these conditions and a lack of resources able to treat them, with research suggesting that a genetic component may be responsible in a number of cases. However, due to the limited genetic investigation diagnosis of men with male reproductive disorders, the wider understanding of the genetics underpinning male hypogonadism and infertility is incomplete. Developments in technology for the investigation and editing of the genetic code are triggering a surge in the exploration of genetic disorders and, in parallel, into the fields of gene delivery vectors and editing technologies. These technologies will allow an expansion into the knowledge and understanding of genetic disorders whilst simultaneously affording the opportunity to exploit this understanding for the development of therapeutics. There have been a small handful of previous studies using technologies such as viral vectors to target the testicular somatic cells and deliver exogenous transgenes with the purpose of both gene editing and repair, all with varying degrees of success. Here, techniques to introduce and target the Leydig and Sertoli cells were investigated to determine the most appropriate methodology for gene delivery to and manipulation of the testis. Refinement of injections into the interstitial compartment were carried out before introducing lentiviral vectors and targeting of Leydig cells was validated and optimised. Lentiviral vectors are able to permanently integrate into the host cell. Surprisingly, analysis of testis post lentiviral injection determined that the lentiviral targeted Leydig cells began to undergo apoptosis one week post injection and were subsequently cleared from the testis after ten days. Contrastingly, this was not the case when adenoviral vectors were introduced into the interstitial compartment, with Leydig cells continuing to express the delivered reporter transgene and, importantly, not expressing markers of apoptosis, ten days post injection. This would suggest that using adenoviral vectors to target the Leydig cell population in the adult testis would be more appropriate than using lentiviral vectors. Previous studies have successfully used lentiviral vectors to target the Sertoli cells in the adult testis via the introduction of the particles through the efferent duct. However, this can result in damage to efferent duct, resulting in blockages and subsequently the seminiferous tubules. To circumvent this, introduction of the lentiviral particles through the rete compartment of the testis at a range of lower injection pressures was examined and injecting at a lower pressure through the rete testis was found to reduce the likelihood of introducing negative impacts on testicular histology when targeting the seminiferous tubules. Using these refined methods of introducing lentiviral vectors, targeted Sertoli cells stably expressed the delivered transgene for up to one year post injection. Using viral vector delivered transgenes for both the investigation of testicular genetic disorders and for the development of therapeutics has great potential. To explore this potential, we first generated a mouse model in which AR was ablated from both the Leydig and Sertoli cells using Cre/LoxP technology, termed the SC-LC-ARKO. Alongside providing a potential model to 'repair' with viral vectors, the SC-LC-ARKO model also provided an additional model for comparison with other models exhibiting ablation of AR from both single somatic cell types and double somatic cell types. This further enabled a characterisation of the roles of AR in adult testicular function, with results suggesting that loss of AR from more than one cell type results in an additive phenotype when compared to single cell knock outs. Despite providing further insight into the roles of AR in the testis, further analysis of the Cre line used to generate the SC-LC-ARKO model indicated that a small number of Leydig cells were expressing the Cre recombinase, resulting in only a small population of Leydig cells with ablated AR. Considering this, to explore the potential of rescuing Sertoli cell AR using lentiviral vectors, we then utilised an already well characterised Sertoli Cell AR knockout (SCARKO) model. Lentiviral vectors expressing mouse AR and monomeric GFP (moeGFP) downstream of a CMV promoter were generated and injected into the rete testis of WT and SCARKO adult (day 100) males at low pressure. The contralateral testis was injected with a lentiviral vector expressing moeGFP alone (also downstream of a CMV promoter) using the same technique. Analysis of testis sections revealed a reintroduction of AR to Sertoli cells in 100% of SCARKO testis injected with lentivirus expressing mouse AR. As a result of this re-expression of AR in Sertoli cells, 66% of the testis injected with lentivirus expressing mouse AR had evidence of morphologically mature elongated spermatids, indicative of ongoing spermatogenesis. These results suggest that a rescue of the infertility phenotype reported in previous studies of SCARKO testis. Also demonstrated is the reversal of the SCARKO testicular phenotype in tubules targeted by the mAR expressing lentiviral vector. This suggests that absence Sertoli cell AR throughout development does not have a permanent impact on the Sertoli cells capacity to support spermatogenesis in adulthood following rescue of SC AR expression in adulthood. In summary, the results of these studies have provided a refinement in the methodologies for targeting the Sertoli and Leydig cells of the adult testis with viral vectors as well as demonstrating successful rescue of a previously reported mouse model exhibiting infertility through reintroduction of a functional gene. Alongside this, comparisons of AR knockout models have afforded insight into maintenance of testis function through AR.

Abstract not available